

Anna P Durbin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5579275/publications.pdf>

Version: 2024-02-01

93
papers

5,075
citations

87401

40
h-index

111975

67
g-index

97
all docs

97
docs citations

97
times ranked

5748
citing authors

#	ARTICLE	IF	CITATIONS
1	Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model. <i>Pathogens</i> , 2022, 11, 294.	1.2	5
2	The innate immune response following multivalent dengue vaccination and implications for protection against dengue challenge. <i>JCI Insight</i> , 2022, 7, .	2.3	5
3	Dengue: A Growing Problem With New Interventions. <i>Pediatrics</i> , 2022, 149, .	1.0	28
4	Cross-reactive antibodies facilitate innate sensing of dengue and Zika viruses. <i>JCI Insight</i> , 2022, 7, .	2.3	2
5	Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response. <i>Vaccine</i> , 2021, 39, 85-120.	1.7	111
6	Building Bridges to Housing for homeless adults with intellectual and developmental disabilities: outcomes of a cross-sector intervention. <i>Journal of Applied Research in Intellectual Disabilities</i> , 2021, 34, 16-27.	1.3	0
7	Health and service use of newcomers and other adults with intellectual and developmental disabilities: A population-based study. <i>Journal of Applied Research in Intellectual Disabilities</i> , 2021, 34, 789-804.	1.3	1
8	A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans. <i>Nature Communications</i> , 2021, 12, 1102.	5.8	40
9	Associations of resilience with quality of life levels in adults experiencing homelessness and mental illness: a longitudinal study. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 74.	1.0	10
10	Immunotranscriptomic profiling the acute and clearance phases of a human challenge dengue virus serotype 2 infection model. <i>Nature Communications</i> , 2021, 12, 3054.	5.8	14
11	The Effect of a Housing First Intervention on Acute Health Care Utilization among Homeless Adults with Mental Illness: Long-term Outcomes of the At Home/Chez-Soi Randomized Pragmatic Trial. <i>Journal of Urban Health</i> , 2021, 98, 505-515.	1.8	10
12	The Impact of Financial Incentives on Service Engagement Among Adults Experiencing Homelessness and Mental Illness: A Pragmatic Trial Protocol. <i>Frontiers in Psychiatry</i> , 2021, 12, 722485.	1.3	3
13	Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera. <i>Journal of Virology</i> , 2021, 95, e0095621.	1.5	8
14	Recovery Education for Adults Transitioning From Homelessness: A Longitudinal Outcome Evaluation. <i>Frontiers in Psychiatry</i> , 2021, 12, 763396.	1.3	2
15	Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees. <i>Cell Reports</i> , 2020, 33, 108226.	2.9	43
16	Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005. <i>Current Opinion in Virology</i> , 2020, 43, 79-87.	2.6	19
17	T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species. <i>Journal of Virology</i> , 2020, 94, .	1.5	49
18	Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. <i>Lancet Infectious Diseases</i> , 2020, 20, 839-850.	4.6	50

#	ARTICLE	IF	CITATIONS
19	Rapid Induction and Maintenance of Virus-Specific CD8+ TEMRA and CD4+ TEM Cells Following Protective Vaccination Against Dengue Virus Challenge in Humans. <i>Frontiers in Immunology</i> , 2020, 11, 479.	2.2	37
20	Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 855-863.	0.6	11
21	Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003. <i>Cell Reports Medicine</i> , 2020, 1, 100155.	3.3	6
22	Prevalence of intellectual and developmental disabilities among first generation adult newcomers, and the health and health service use of this group: A retrospective cohort study. <i>PLoS ONE</i> , 2019, 14, e0215804.	1.1	7
23	What is the prospect of a safe and effective dengue vaccine for travellers?. <i>Journal of Travel Medicine</i> , 2019, 26, .	1.4	14
24	Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines. <i>Journal of Infectious Diseases</i> , 2019, 220, 219-227.	1.9	22
25	Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model. <i>EBioMedicine</i> , 2019, 41, 465-478.	2.7	31
26	The intersection of intellectual and developmental disabilities and HIV: A scoping review. <i>Journal of Intellectual and Developmental Disability</i> , 2019, 44, 346-356.	1.1	2
27	Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. <i>Vaccine</i> , 2018, 36, 3411-3417.	1.7	52
28	Rapid changes in serum cytokines and chemokines in response to inactivated influenza vaccination. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 202-210.	1.5	25
29	Cutting Edge: Transcriptional Profiling Reveals Multifunctional and Cytotoxic Antiviral Responses of Zika Virus-Specific CD8+ T Cells. <i>Journal of Immunology</i> , 2018, 201, 3487-3491.	0.4	70
30	Development of standard clinical endpoints for use in dengue interventional trials. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006497.	1.3	29
31	Impact of Dengue Virus Serotype 2 Strain Diversity on Serological Immune Responses to Dengue. <i>ACS Infectious Diseases</i> , 2018, 4, 1705-1717.	1.8	2
32	Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006862.	1.3	93
33	Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization. <i>Cell Reports</i> , 2018, 25, 1214-1224.	2.9	50
34	Intellectual Disability and Homelessness: a Synthesis of the Literature and Discussion of How Supportive Housing Can Support Wellness for People with Intellectual Disability. <i>Current Developmental Disorders Reports</i> , 2018, 5, 125-131.	0.9	15
35	Zika vaccines and therapeutics: landscape analysis and challenges ahead. <i>BMC Medicine</i> , 2018, 16, 84.	2.3	70
36	Early Transcriptional Responses After Dengue Vaccination Mirror the Response to Natural Infection and Predict Neutralizing Antibody Titers. <i>Journal of Infectious Diseases</i> , 2018, 218, 1911-1921.	1.9	13

#	ARTICLE	IF	CITATIONS
37	The Effect of Housing First on Housing Stability for People with Mental Illness and Low Intellectual Functioning. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 785-789.	0.9	9
38	Emergency Department Use: Common Presenting Issues and Continuity of Care for Individuals With and Without Intellectual and Developmental Disabilities. <i>Journal of Autism and Developmental Disorders</i> , 2018, 48, 3542-3550.	1.7	18
39	Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes. <i>PLoS Pathogens</i> , 2018, 14, e1006934.	2.1	35
40	A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4 ^Δ 30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers. <i>Journal of Infectious Diseases</i> , 2017, 215, 52-55.	1.9	16
41	Antibody Responses to Zika Virus Infections in Environments of Flavivirus Endemicity. <i>Vaccine Journal</i> , 2017, 24, .	3.2	48
42	Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2 ^Δ 30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain. <i>Journal of Virology</i> , 2017, 91, .	1.5	24
43	An update on Zika vaccine developments. <i>Expert Review of Vaccines</i> , 2017, 16, 781-787.	2.0	46
44	Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination. <i>Journal of Virology</i> , 2017, 91, .	1.5	44
45	Human CD4 ⁺ T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity. <i>Journal of Virology</i> , 2017, 91, .	1.5	83
46	Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans. <i>Journal of Virology</i> , 2017, 91, .	1.5	148
47	Dengue vaccines. <i>Current Opinion in Infectious Diseases</i> , 2017, 30, 449-454.	1.3	24
48	Immune correlates of protection for dengue: State of the art and research agenda. <i>Vaccine</i> , 2017, 35, 4659-4669.	1.7	81
49	Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4. <i>Scientific Reports</i> , 2017, 7, 17169.	1.6	23
50	Mental Health Disorders and Publicly Funded Service Use by HIV Positive Individuals: A Population-Based Cross-Sectional Study in Ontario, Canada. <i>AIDS and Behavior</i> , 2017, 21, 3457-3463.	1.4	2
51	Zika Vaccines: Role for Controlled Human Infection. <i>Journal of Infectious Diseases</i> , 2017, 216, S971-S975.	1.9	17
52	Global Assessment of Dengue Virus-Specific CD4 ⁺ T Cell Responses in Dengue-Endemic Areas. <i>Frontiers in Immunology</i> , 2017, 8, 1309.	2.2	77
53	In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005584.	1.3	94
54	Dengue Antibody and Zika: Friend or Foe?. <i>Trends in Immunology</i> , 2016, 37, 635-636.	2.9	36

#	ARTICLE	IF	CITATIONS
55	Vaccine Development for Zika Virus—Timelines and Strategies. <i>Seminars in Reproductive Medicine</i> , 2016, 34, 299-304.	0.5	41
56	The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. <i>Science Translational Medicine</i> , 2016, 8, 330ra36.	5.8	227
57	A Dengue Vaccine. <i>Cell</i> , 2016, 166, 1.	13.5	98
58	Status of vaccine research and development of vaccines for dengue. <i>Vaccine</i> , 2016, 34, 2934-2938.	1.7	97
59	A 12-Month Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response. <i>Journal of Infectious Diseases</i> , 2016, 214, 832-835.	1.9	51
60	Safety and Immunogenicity of Pfs25-EPA/Alhydrogel [®] , a Transmission Blocking Vaccine against <i>Plasmodium falciparum</i> : An Open Label Study in Malaria Naïve Adults. <i>PLoS ONE</i> , 2016, 11, e0163144.	1.1	114
61	Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali. <i>Clinical Infectious Diseases</i> , 2015, 61, S493-S500.	2.9	14
62	The dengue vaccine pipeline: Implications for the future of dengue control. <i>Vaccine</i> , 2015, 33, 3293-3298.	1.7	109
63	Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naïve Adults. <i>Journal of Infectious Diseases</i> , 2015, 212, 702-710.	1.9	158
64	Dengue human infection models to advance dengue vaccine development. <i>Vaccine</i> , 2015, 33, 7075-7082.	1.7	44
65	Dengue viruses cluster antigenically but not as discrete serotypes. <i>Science</i> , 2015, 349, 1338-1343.	6.0	195
66	The Human CD8 ⁺ T Cell Responses Induced by a Live Attenuated Tetravalent Dengue Vaccine Are Directed against Highly Conserved Epitopes. <i>Journal of Virology</i> , 2015, 89, 120-128.	1.5	148
67	1478Dermatologic Manifestations in Live Attenuated Dengue Vaccines: A Skin Biopsy Study. <i>Open Forum Infectious Diseases</i> , 2014, 1, S390-S391.	0.4	0
68	Examining Patient Race and Area Predictors of Inpatient Admission for Schizophrenia Among Hospital Users in California. <i>Journal of Immigrant and Minority Health</i> , 2014, 16, 1025-1034.	0.8	13
69	Viral kinetics of primary dengue virus infection in non-human primates: A systematic review and individual pooled analysis. <i>Virology</i> , 2014, 452-453, 237-246.	1.1	43
70	Mechanism and Significance of Cell Type-Dependent Neutralization of Flaviviruses. <i>Journal of Virology</i> , 2014, 88, 7210-7220.	1.5	58
71	Long-term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation. <i>Vaccine</i> , 2013, 31, 2603-2609.	1.7	37
72	The live attenuated chimeric vaccine rWN/DEN4 ^Δ 30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers. <i>Vaccine</i> , 2013, 31, 5772-5777.	1.7	47

#	ARTICLE	IF	CITATIONS
73	Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity. <i>Virology</i> , 2013, 439, 34-41.	1.1	24
74	A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naïve Adults: A Randomized, Double-blind Clinical Trial. <i>Journal of Infectious Diseases</i> , 2013, 207, 957-965.	1.9	147
75	The Type-Specific Neutralizing Antibody Response Elicited by a Dengue Vaccine Candidate Is Focused on Two Amino Acids of the Envelope Protein. <i>PLoS Pathogens</i> , 2013, 9, e1003761.	2.1	34
76	The Dengue Human Challenge Model: Has the Time Come to Accept This Challenge?. <i>Journal of Infectious Diseases</i> , 2013, 207, 697-699.	1.9	27
77	Primary Vaccination with Low Dose Live Dengue 1 Virus Generates a Proinflammatory, Multifunctional T Cell Response in Humans. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1742.	1.3	35
78	Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. <i>Vaccine</i> , 2011, 29, 7242-7250.	1.7	104
79	A Single Dose of the DENV-1 Candidate Vaccine rDEN1 ³⁰ Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1267.	1.3	42
80	Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development. <i>Viruses</i> , 2011, 3, 1800-1814.	1.5	48
81	Heterotypic Dengue Infection with Live Attenuated Monotypic Dengue Virus Vaccines: Implications for Vaccination of Populations in Areas Where Dengue Is Endemic. <i>Journal of Infectious Diseases</i> , 2011, 203, 327-334.	1.9	41
82	Dengue Vaccine Candidates in Development. <i>Current Topics in Microbiology and Immunology</i> , 2010, 338, 129-143.	0.7	79
83	Monitoring adverse events following yellow fever vaccination using an integrated telephone and Internet-based system. <i>Vaccine</i> , 2009, 27, 6143-6147.	1.7	12
84	Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. <i>Virology</i> , 2008, 376, 429-435.	1.1	190
85	Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers. <i>Vaccine</i> , 2008, 26, 882-890.	1.7	28
86	Phase I Clinical Evaluation of rDEN4 ^{30-200,201} : A Live Attenuated Dengue 4 Vaccine Candidate Designed for Decreased Hepatotoxicity. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 79, 678-684.	0.6	51
87	Phase I clinical evaluation of rDEN4 ^{Delta30-200,201} : a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 79, 678-84.	0.6	29
88	Prospects for a dengue virus vaccine. <i>Nature Reviews Microbiology</i> , 2007, 5, 518-528.	13.6	513
89	The Live Attenuated Dengue Serotype 1 Vaccine rDEN1 ^{&Delta;30} is Safe and Highly Immunogenic in Healthy Adult Volunteers. <i>Hum Vaccin</i> , 2006, 2, 167-173.	2.4	89
90	rDEN2/4 ^{30(ME)} , a Live Attenuated Chimeric Dengue Serotype 2 Vaccine, is Safe and Highly Immunogenic in Healthy Dengue-Naïve Adults. <i>Hum Vaccin</i> , 2006, 2, 255-260.	2.4	93

#	ARTICLE	IF	CITATIONS
91	rDEN4 ¹ 30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers. <i>Journal of Infectious Diseases</i> , 2005, 191, 710-718.	1.9	124
92	Progress in the Development of Respiratory Syncytial Virus and Parainfluenza Virus Vaccines. <i>Clinical Infectious Diseases</i> , 2003, 37, 1668-1677.	2.9	77
93	Intensive Use of Forensic Inpatient Services by People with Intellectual and Developmental Disabilities in Ontario, Canada: Prevalence and Associated Characteristics. <i>International Journal of Forensic Mental Health</i> , 0, , 1-12.	0.6	4